摘要
为使禽流感H9N2病毒样颗粒疫苗尽早投入市场,有效防控H9N2禽流感的流行,拟从油乳、ISA 206和微球佐剂中筛选出一种最适用于禽流感H9N2病毒样颗粒疫苗的佐剂。首先对H9N2病毒样颗粒血凝效价及血凝素(HA)含量的测定,然后制备出禽流感H9N2病毒样颗粒油乳疫苗、ISA 206佐剂疫苗、微球疫苗,并对其稳定性、无菌性和安全性等进行检验。通过溶菌酶含量、血凝抑制试验以及T淋巴细胞刺激指数等试验检测其非特异性免疫和特异性免疫水平。结果表明:微球VLP疫苗组溶菌酶含量高于其他各疫苗组(p﹤0.01),能引起非特异性免疫;微球VLPs(口服)疫苗组的血凝抑制滴度高于其他各疫苗组(p﹤0.01),抗体增长趋势与阳性对照组无显著差异(p>0.05),产生了有效的体液免疫应答;微球VLP疫苗(口服)疫苗组T淋巴细胞刺激指数最高。微球口服疫苗其免疫原性强,安全稳定,能诱导机体产生有效的免疫应答,可为新型病毒样颗粒疫苗佐剂的选择提供参考。
In order to have effectively prevention and control of avian influenza H9N2 pandemic,three kind of adjuvanted avian influenza H9N2 virus-like particle vaccines( oil-emulsion,ISA 206 and microspheres) were developed and selected to get the best one for avian influenza H9N2 VLPs by immunity evaluation in chicken. The HA assay was performed to demonstrate the agglutination activity of VLPs and the HA protein content was evaluated by the standard quantification method that is indirect ELISA assay. Then the stability,sterility and security of H9N2 VLPs vaccines were tested before vaccination. HI assay was used to assess the functional antibodies in the sera of immunized chicken to HA. Determination of T lymphocyte stimulation index and lysozyme content were investigated by MTT and lysozyme content detection kit. The results show that chicken orally vaccinated with the microspheres H9N2 VLPs generated higher lysozyme content and HI titers of antibody against H9N2 viruses than other groups( p < 0. 01) and little or no cellular immune response.The microspheres H9N2 VLPs vaccines provided the best safety,sterility and immunogenicity to chicken and these results indicate a reference for the choice of adjuvanted avian influenza H9N2 VLPs vaccines.
出处
《重庆理工大学学报（自然科学）》
CAS
2017年第5期99-104,147,共7页
Journal of Chongqing University of Technology：Natural Science
基金
重庆高校优秀成果转化资助项目(KJZH14212)
